Your browser doesn't support javascript.
loading
Repeat Flow Diversion for Cerebral Aneurysms Failing Prior Flow Diversion: Safety and Feasibility From Multicenter Experience.
Salem, Mohamed M; Sweid, Ahmad; Kuhn, Anna L; Dmytriw, Adam A; Gomez-Paz, Santiago; Maragkos, Georgios A; Waqas, Muhammad; Parra-Farinas, Carmen; Salehani, Arsalaan; Adeeb, Nimer; Brouwer, Patrick; Pickett, Gwynedd; Ku, Jerry; X D Yang, Victor; Weill, Alain; Radovanovic, Ivan; Cognard, Christophe; Spears, Julian; Cuellar-Saenz, Hugo H; Renieri, Leonardo; Kan, Peter; Limbucci, Nicola; Mendes Pereira, Vitor; Harrigan, Mark R; Puri, Ajit S; Levy, Elad I; Moore, Justin M; Ogilvy, Christopher S; Marotta, Thomas R; Jabbour, Pascal; Thomas, Ajith J.
Afiliación
  • Salem MM; Division of Neurosurgery, Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, MA (M.M.S., S.G.-P., G.A.M., J.M.M., C.S.O., A.J.T.).
  • Sweid A; Department of Neurosurgery, Thomas Jefferson University Hospitals, Philadelphia, PA (A.S., P.J.).
  • Kuhn AL; Division of Interventional Neuroradiology, Department of Radiology, University of Massachusetts Medical Center, Worcester (A.L.K., A.S.P.).
  • Dmytriw AA; Department of Medical Imaging and Surgery, Toronto Western Hospital, University Health Network, ON, Canada (A.A.D., I.R., V.M.P.).
  • Gomez-Paz S; Division of Neurosurgery, Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, MA (M.M.S., S.G.-P., G.A.M., J.M.M., C.S.O., A.J.T.).
  • Maragkos GA; Division of Neurosurgery, Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, MA (M.M.S., S.G.-P., G.A.M., J.M.M., C.S.O., A.J.T.).
  • Waqas M; Department of Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, NY (M.W., E.I.L.).
  • Parra-Farinas C; Departments of Therapeutic Neuroradiology (C.P.-F., J.S., T.R.M.), St. Michael's Hospital, Toronto, ON, Canada.
  • Salehani A; Surgery (C.P.-F., J.S., T.R.M.), St. Michael's Hospital, Toronto, ON, Canada.
  • Adeeb N; Department of Neurosurgery, University of Alabama at Birmingham (A.S., M.R.H.).
  • Brouwer P; Department of Neurosurgery, Ochsner-Louisiana State University Hospital, Shreveport (N.A., H.H.C.-S.).
  • Pickett G; Department of Neuroradiology, Karolinska Universitetssjukhuset, Stockholm, Sweden (P.B.).
  • Ku J; Division of Neurosurgery, Dalhousie University, Halifax, Nova Scotia, Canada (G.P.).
  • X D Yang V; Department of Neuroradiology and Neurosurgery, Sunnybrook Health Sciences Centre, Toronto, ON, Canada (J.K., V.X.D.Y.).
  • Weill A; Department of Neuroradiology and Neurosurgery, Sunnybrook Health Sciences Centre, Toronto, ON, Canada (J.K., V.X.D.Y.).
  • Radovanovic I; Department of Radiology, Service of Neuroradiology, Centre Hospitalier de l'Université de Montréal, QC, Canada (A.W.).
  • Cognard C; Department of Medical Imaging and Surgery, Toronto Western Hospital, University Health Network, ON, Canada (A.A.D., I.R., V.M.P.).
  • Spears J; Department of Diagnostic and Therapeutic Neuroradiology, University Hospital of Toulouse, France (C.C.).
  • Cuellar-Saenz HH; Departments of Therapeutic Neuroradiology (C.P.-F., J.S., T.R.M.), St. Michael's Hospital, Toronto, ON, Canada.
  • Renieri L; Surgery (C.P.-F., J.S., T.R.M.), St. Michael's Hospital, Toronto, ON, Canada.
  • Kan P; Department of Neurosurgery, Ochsner-Louisiana State University Hospital, Shreveport (N.A., H.H.C.-S.).
  • Limbucci N; Department of Interventional Neuroradiology, University of Florence, Florence, Italy (L.R., N.L.).
  • Mendes Pereira V; Department of Neurosurgery, Baylor College of Medicine, Houston, TX (P.K.).
  • Harrigan MR; Department of Interventional Neuroradiology, University of Florence, Florence, Italy (L.R., N.L.).
  • Puri AS; Department of Medical Imaging and Surgery, Toronto Western Hospital, University Health Network, ON, Canada (A.A.D., I.R., V.M.P.).
  • Levy EI; Department of Neurosurgery, University of Alabama at Birmingham (A.S., M.R.H.).
  • Moore JM; Division of Interventional Neuroradiology, Department of Radiology, University of Massachusetts Medical Center, Worcester (A.L.K., A.S.P.).
  • Ogilvy CS; Department of Neurosurgery, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, NY (M.W., E.I.L.).
  • Marotta TR; Division of Neurosurgery, Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, MA (M.M.S., S.G.-P., G.A.M., J.M.M., C.S.O., A.J.T.).
  • Jabbour P; Division of Neurosurgery, Beth Israel Deaconess Medical Center, Harvard Teaching Hospital, Boston, MA (M.M.S., S.G.-P., G.A.M., J.M.M., C.S.O., A.J.T.).
  • Thomas AJ; Departments of Therapeutic Neuroradiology (C.P.-F., J.S., T.R.M.), St. Michael's Hospital, Toronto, ON, Canada.
Stroke ; 53(4): 1178-1189, 2022 04.
Article en En | MEDLINE | ID: mdl-34634924
ABSTRACT

BACKGROUND:

Aneurysmal persistence after flow diversion (FD) occurs in 5% to 25% of aneurysms, which may necessitate retreatment. There are limited data on safety/efficacy of repeat FD-a frequently utilized strategy in such cases.

METHODS:

A series of consecutive patients undergoing FD retreatment from 15 centers were reviewed (2011-2019), with inclusion criteria of repeat FD for the same aneurysm at least 6 months after initial treatment, with minimum of 6 months post-retreatment imaging. The primary outcome was aneurysmal occlusion, and secondary outcome was safety. A multivariable logistic regression model was constructed to identify predictors of incomplete occlusion (90%-99% and <90% occlusion) versus complete occlusion (100%) after retreatment.

RESULTS:

Ninety-five patients (median age, 57 years; 81% women) harboring 95 aneurysms underwent 198 treatment procedures. Majority of aneurysms were unruptured (87.4%), saccular (74.7%), and located in the internal carotid artery (79%; median size, 9 mm). Median elapsed time between the first and second treatment was 12.2 months. Last available follow-up was at median 12.8 months after retreatment, and median 30.6 months after the initial treatment, showing complete occlusion in 46.2% and near-complete occlusion (90%-99%) in 20.4% of aneurysms. There was no difference in ischemic complications following initial treatment and retreatment (4.2% versus 4.2%; P>0.99). On multivariable regression, fusiform morphology had higher nonocclusion odds after retreatment (odds ratio [OR], 7.2 [95% CI, 1.97-20.8]). Family history of aneurysms was associated with lower odds of nonocclusion (OR, 0.18 [95% CI, 0.04-0.78]). Likewise, positive smoking history was associated with lower odds of nonocclusion (OR, 0.29 [95% CI, 0.1-0.86]). History of hypertension trended toward incomplete occlusion (OR, 3.10 [95% CI, 0.98-6.3]), similar to incorporated branch into aneurysms (OR, 2.78 [95% CI, 0.98-6.8]).

CONCLUSIONS:

Repeat FD for persistent aneurysms carries a reasonable success/safety profile. Satisfactory occlusion (100% and 90%-99% occlusion) was encountered in two-thirds of patients, with similar complications between the initial and subsequent retreatments. Fusiform morphology was the strongest predictor of retreatment failure.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Aneurisma Intracraneal / Mordida Abierta / Embolización Terapéutica / Procedimientos Endovasculares Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Stroke Año: 2022 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Aneurisma Intracraneal / Mordida Abierta / Embolización Terapéutica / Procedimientos Endovasculares Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Stroke Año: 2022 Tipo del documento: Article